Avenue Therapeutics, Inc. (NASDAQ:ATXI – Get Free Report) shares rose 20.7% on Tuesday . The company traded as high as $0.3807 and last traded at $0.35. Approximately 6,078 shares changed hands during trading, a decline of 27% from the average daily volume of 8,382 shares. The stock had previously closed at $0.29.
Avenue Therapeutics Stock Performance
The stock has a 50 day moving average price of $0.24 and a two-hundred day moving average price of $0.55. The company has a market capitalization of $1.15 million, a PE ratio of 0.02 and a beta of -0.93.
About Avenue Therapeutics
Avenue Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel therapies for disorders of the central nervous system, with an initial emphasis on acute pain management. The company’s research and development efforts are centered on reformulating established active pharmaceutical ingredients to address unmet needs in hospital and outpatient settings, aiming to improve safety profiles, reduce opioid exposure and support enhanced patient recovery.
The company’s lead product candidate is intravenous tramadol, a unique non-solicited opioid analgesic that combines dual mechanisms of action to manage moderate to severe acute pain.
Featured Stories
Receive News & Ratings for Avenue Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Avenue Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
